LYMPHOMAS

September 5th 2024

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients with lymphoma.

August 16th 2024

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

August 8th 2024

Following voluntary withdrawal in 2014, denileukin diftitox is now available again for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

July 7th 2024

The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.